| Patients with monotherapy (n = 114) | Patients with polypharmacy (n = 69) | P value | ||
---|---|---|---|---|---|
 | M | (SD)1 | M | (SD) |  |
Socio-demographic characteristics | Â | Â | Â | Â | Â |
Gender (male), N (%)2 | 79 | (69.3) | 50 | (73.5) | 0.54 |
Age | 37.9 | (10.5) | 40.6 | (10.3) | 0.08 |
Living conditions (Alone), N (%) | 35 | (30.7) | 30 | (43.5) | 0.08 |
Clinical characteristics | Â | Â | Â | Â | Â |
Age at onset of illness | 25.43 | (8.20) | 22.65 | (7.28) | 0.03 |
Total PANSS3 score | 65.3 | (18.0) | 70.0 | (22.2) | 0.14 |
   Positive PANSS score | 14.0 | (5.3) | 13.7 | (5.6) | 0.74 |
   Negative PANSS score | 18.0 | (6.9) | 19.6 | (8.2) | 0.16 |
   General Psychopathology PANSS score | 33.3 | (9.8) | 36.7 | (11.6) | 0.04 |
GAF4 score | 54.0 | (14.0) | 51.0 | (16.3) | 0.20 |
GARF5 score | 55.7 | (16.7) | 54.3 | (17.7) | 0.59 |
SOFAS6 score | 53.9 | (13.4) | 50.7 | (15.7) | 0.15 |
CDSS7 score | 2.7 | (3.3) | 3.8 | (4.1) | 0.07 |
Medication | Â | Â | Â | Â | Â |
Drugs for side-effects§, N (%) | 40 | (35.0) | 42 | (60.9) | <0.01 |
Sedative drugs§§, N (%) | 49 | (43.0) | 46 | (66.7) | <0.01 |
Antidepressant, N (%) | 18 | (15.8) | 20 | (29.0) | 0.03 |
AIMS8 | 2.7 | (4.3) | 3.1 | (4.6) | 0.53 |
BAS9 | 1.0 | (1.9) | 1.1 | (2.1) | 0.71 |
SAS10 | 2.9 | (3.3) | 3.8 | (4.0) | 0.13 |
ROMI11 | Â | Â | Â | Â | Â |
Compliance score | 12.2 | (2.8) | 13.0 | (2.7) | 0.09 |
Non compliance score | 14.2 | (3.7) | 14.0 | (3.8) | 0.74 |
Number of previous hospitalisations | 5.5 | (5.3) | 7.5 | (6.9) | 0.05 |
Quality of life: SF-36 | Â | Â | Â | Â | Â |
Physical Functioning | 82.0 | (20.5) | 76.3 | (22.9) | 0.10 |
Role-Physical Limitations | 74.2 | (32.9) | 65.9 | (40.2) | 0.15 |
Bodily Pain | 72.7 | (26.3) | 71.9 | (27.6) | 0.85 |
General Health | 58.2 | (21.4) | 58.3 | (21.0) | 0.98 |
Vitality | 50.9 | (19.1) | 48.0 | (17.9) | 0.34 |
Mental Health | 63.4 | (20.4) | 59.5 | (17.3) | 0.21 |
Role-Emotional Limitations | 74.3 | (36.4) | 60.8 | (40.2) | 0.03 |
Social Functioning | 68.9 | (30.1) | 67.1 | (25.8) | 0.70 |
Relapse, N (%) | 27 | (23.7) | 23 | (33.3) | 0.16 |